G. Hoffmann

Dihydrospirorenone (ZK30595): a novel synthetic progestagen--characterization of binding to different receptor proteins.

V. Möbus, K. Pollow, W. Elger, 1992, Contraception.

[GnRH-agonists in the therapy of endometriosis].

J. Spitz, G. Hoffmann, R. Behrens, 1990, Therapeutische Umschau. Revue therapeutique.

3H‐estradiol and 3H‐R5020 binding in cytosols of normal and neoplastic human ovarian tissue

R. Kreienberg, K. Pollow, B. Manz, 1983, International journal of cancer.

Characterization of human spleen tumor glucocorticoid receptors using [3H]cortisol as ligand.

K. Pollow, B. Manz, H. Grill, 1984, Journal of steroid biochemistry.

Urokinase and Plasminogen Activator-Inhibitor (PAI-1) Status in Primary Ovarian Carcinomas and Ovarian Metastases Compared to Benign Ovarian Tumors as A Function of Histopathological Parameters

H. Strittmatter, W. Weikel, P. Knapstein, 1999, Clinical chemistry and laboratory medicine.

Receptor binding of norgestimate--a new orally active synthetic progestational compound.

V. Möbus, K. Pollow, W. Elger, 1993, Contraception.

Basic and clinical relevance of hormonal influence in breast cancer.

R. Kreienberg, K. Pollow, B. Manz, 1990, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[Results of long-term follow-up in treatment of endometriosis with the GnRH agonist leuprorelin acetate depot (Enantone-Gyn monthly depot)].

R. Kimmig, A. Schindler, I. Gerhard, 1996, Zentralblatt fur Gynakologie.

Treatment of endometriosis with leuprorelin acetate depot: a German multicentre study.

R. Kimmig, A. Schindler, I. Gerhard, 1992, Clinical therapeutics.

Safety and tolerability of adjuvant exemestane plus goserelin with or without tibolone in receptor-positive, node-negative primary breast cancer in premenopausal women: The final results of the randomized multicenter ADAGIO pilot study.

K. Winzer, R. Kreienberg, H. Koelbl, 2004, Journal of Clinical Oncology.